EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
8.58
-0.18 (-2.06%)
Dec 3, 2024, 12:14 PM EST - Market open
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees as of December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$377,793
Profits / Employee
-$855,950
Market Cap
601.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Phathom Pharmaceuticals | 452 |
Axogen | 428 |
Sana Biotechnology | 328 |
Simulations Plus | 247 |
OrthoPediatrics | 247 |
Monte Rosa Therapeutics | 133 |
Stoke Therapeutics | 110 |
Altimmune | 59 |
EYPT News
- 19 days ago - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
- 4 weeks ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewsWire
- 4 weeks ago - EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 6 weeks ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire